Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80


Both CD31(+) and CD31⁻ naive CD4(+) T cells are persistent HIV type 1-infected reservoirs in individuals receiving antiretroviral therapy.

Wightman F, Solomon A, Khoury G, Green JA, Gray L, Gorry PR, Ho YS, Saksena NK, Hoy J, Crowe SM, Cameron PU, Lewin SR.

J Infect Dis. 2010 Dec 1;202(11):1738-48. doi: 10.1086/656721. Epub 2010 Oct 27.


Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy.

Yukl SA, Gianella S, Sinclair E, Epling L, Li Q, Duan L, Choi AL, Girling V, Ho T, Li P, Fujimoto K, Lampiris H, Hare CB, Pandori M, Haase AT, Günthard HF, Fischer M, Shergill AK, McQuaid K, Havlir DV, Wong JK.

J Infect Dis. 2010 Nov 15;202(10):1553-61. doi: 10.1086/656722. Epub 2010 Oct 12.


Treatment intensification has no effect on the HIV-1 central nervous system infection in patients on suppressive antiretroviral therapy.

Yilmaz A, Verhofstede C, D'Avolio A, Watson V, Hagberg L, Fuchs D, Svennerholm B, Gisslén M.

J Acquir Immune Defic Syndr. 2010 Dec 15;55(5):590-6. doi: 10.1097/QAI.0b013e3181f5b3d1.


Establishment of HIV-1 latency in resting CD4+ T cells depends on chemokine-induced changes in the actin cytoskeleton.

Cameron PU, Saleh S, Sallmann G, Solomon A, Wightman F, Evans VA, Boucher G, Haddad EK, Sekaly RP, Harman AN, Anderson JL, Jones KL, Mak J, Cunningham AL, Jaworowski A, Lewin SR.

Proc Natl Acad Sci U S A. 2010 Sep 28;107(39):16934-9. doi: 10.1073/pnas.1002894107. Epub 2010 Sep 13.


Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy.

Yukl SA, Shergill AK, McQuaid K, Gianella S, Lampiris H, Hare CB, Pandori M, Sinclair E, Günthard HF, Fischer M, Wong JK, Havlir DV.

AIDS. 2010 Oct 23;24(16):2451-60. doi: 10.1097/QAD.0b013e32833ef7bb.


Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.

Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, Kharsany AB, Sibeko S, Mlisana KP, Omar Z, Gengiah TN, Maarschalk S, Arulappan N, Mlotshwa M, Morris L, Taylor D; CAPRISA 004 Trial Group.

Science. 2010 Sep 3;329(5996):1168-74. doi: 10.1126/science.1193748. Epub 2010 Jul 19. Erratum in: Science. 2011 Jul 29;333(6042):524.


Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo.

Holt N, Wang J, Kim K, Friedman G, Wang X, Taupin V, Crooks GM, Kohn DB, Gregory PD, Holmes MC, Cannon PM.

Nat Biotechnol. 2010 Aug;28(8):839-47. doi: 10.1038/nbt.1663. Epub 2010 Jul 2.


RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma.

DiGiusto DL, Krishnan A, Li L, Li H, Li S, Rao A, Mi S, Yam P, Stinson S, Kalos M, Alvarnas J, Lacey SF, Yee JK, Li M, Couture L, Hsu D, Forman SJ, Rossi JJ, Zaia JA.

Sci Transl Med. 2010 Jun 16;2(36):36ra43. doi: 10.1126/scitranslmed.3000931.


Long-term immunovirologic control following antiretroviral therapy interruption in patients treated at the time of primary HIV-1 infection.

Hocqueloux L, Prazuck T, Avettand-Fenoel V, Lafeuillade A, Cardon B, Viard JP, Rouzioux C.

AIDS. 2010 Jun 19;24(10):1598-601.


Public health. Global HIV/AIDS policy in transition.

Bongaarts J, Over M.

Science. 2010 Jun 11;328(5984):1359-60. doi: 10.1126/science.1191804. No abstract available.


Semen may harbor HIV despite effective HAART: another piece in the puzzle.

Halfon P, Giorgetti C, Khiri H, Pénaranda G, Terriou P, Porcu-Buisson G, Chabert-Orsini V.

PLoS One. 2010 May 13;5(5):e10569. doi: 10.1371/journal.pone.0010569.


Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection.

Neuhaus J, Jacobs DR Jr, Baker JV, Calmy A, Duprez D, La Rosa A, Kuller LH, Pett SL, Ristola M, Ross MJ, Shlipak MG, Tracy R, Neaton JD.

J Infect Dis. 2010 Jun 15;201(12):1788-95. doi: 10.1086/652749.


Control of HIV-1 in elite suppressors despite ongoing replication and evolution in plasma virus.

O'Connell KA, Brennan TP, Bailey JR, Ray SC, Siliciano RF, Blankson JN.

J Virol. 2010 Jul;84(14):7018-28. doi: 10.1128/JVI.00548-10. Epub 2010 May 5.


Combinatorial latency reactivation for HIV-1 subtypes and variants.

Burnett JC, Lim KI, Calafi A, Rossi JJ, Schaffer DV, Arkin AP.

J Virol. 2010 Jun;84(12):5958-74. doi: 10.1128/JVI.00161-10. Epub 2010 Mar 31.


HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects.

Buzón MJ, Massanella M, Llibre JM, Esteve A, Dahl V, Puertas MC, Gatell JM, Domingo P, Paredes R, Sharkey M, Palmer S, Stevenson M, Clotet B, Blanco J, Martinez-Picado J.

Nat Med. 2010 Apr;16(4):460-5. doi: 10.1038/nm.2111. Epub 2010 Mar 14.


HIV-1 infects multipotent progenitor cells causing cell death and establishing latent cellular reservoirs.

Carter CC, Onafuwa-Nuga A, McNamara LA, Riddell J 4th, Bixby D, Savona MR, Collins KL.

Nat Med. 2010 Apr;16(4):446-51. doi: 10.1038/nm.2109. Epub 2010 Mar 7.


Risk of all-cause mortality associated with nonfatal AIDS and serious non-AIDS events among adults infected with HIV.

Neuhaus J, Angus B, Kowalska JD, La Rosa A, Sampson J, Wentworth D, Mocroft A; INSIGHT SMART and ESPRIT study groups.

AIDS. 2010 Mar 13;24(5):697-706. doi: 10.1097/QAD.0b013e3283365356.


Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy.

McMahon D, Jones J, Wiegand A, Gange SJ, Kearney M, Palmer S, McNulty S, Metcalf JA, Acosta E, Rehm C, Coffin JM, Mellors JW, Maldarelli F.

Clin Infect Dis. 2010 Mar 15;50(6):912-9. doi: 10.1086/650749.


Critical choices in financing the response to the global HIV/AIDS pandemic.

Hecht R, Bollinger L, Stover J, McGreevey W, Muhib F, Madavo CE, de Ferranti D.

Health Aff (Millwood). 2009 Nov-Dec;28(6):1591-605. doi: 10.1377/hlthaff.28.6.1591. Erratum in: Health Aff (Millwood). 2010 Jan-Feb;29(1):223.

Supplemental Content

Support Center